{
  "author": {
    "name": "Bailey Lipschultz",
    "webUrl": "/author/profile/bailey-lipschultz/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 3,
    "social": [],
    "articles": [
      {
        "uri": "/2018/12/14/health-investors-get-selective-as-markets-churn-in/",
        "title": "Health investors get selective as markets churn into 2019",
        "byline": "Bailey Lipschultz",
        "kicker": "Market Insights",
        "prettyDate": "December 14, 2018",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/12/pill-money-investing-investments-health-pharma.jpg",
          "width": "616",
          "height": "411"
        },
        "authors": [
          {
            "webUrl": "/author/profile/bailey-lipschultz/",
            "name": "Bailey Lipschultz"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "For those looking to pick new investments or add to positions on companies that have fallen out of bed, the time may be now.",
        "body": null
      },
      {
        "uri": "/2018/11/26/gene-editing-stocks-gain-after-doctor-claims-succe/",
        "title": "Gene-editing stocks gain after doctor claims success in babies",
        "byline": "Bailey Lipschultz",
        "kicker": "Market Insights",
        "prettyDate": "November 26, 2018",
        "timeToRead": "2 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/11/dna-getty.jpg",
          "width": "600",
          "height": "456"
        },
        "authors": [
          {
            "webUrl": "/author/profile/bailey-lipschultz/",
            "name": "Bailey Lipschultz"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "The trio of public companies developing therapies using the technology known as Crispr outperformed peers.",
        "body": null
      },
      {
        "uri": "/2018/06/29/analyst-reactions-to-amazons-pharma-acquisition/",
        "title": "Analyst reactions to Amazon's pharma acquisition",
        "byline": "Bailey Lipschultz",
        "kicker": "Commentary",
        "prettyDate": "June 29, 2018",
        "timeToRead": "1 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/06/amazon-crop-600x3381-crop-600x338.jpg",
          "width": "600",
          "height": "338"
        },
        "authors": [
          {
            "webUrl": "/author/profile/bailey-lipschultz/",
            "name": "Bailey Lipschultz"
          }
        ],
        "kickerNode": [
          {
            "uri": "/commentary/",
            "sectionName": "Commentary"
          }
        ],
        "summary": "While speculation about Amazon entering the health-care space has plagued the sector for months, one analyst calls the latest move “a full frontal attack.”",
        "body": null
      }
    ]
  }
}